Double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in NSCLC

Rosalyn Juergens, MD, PhD of McMaster University, Juravinski Cancer Centre, Canada talks about the Canadian Clinical Trials Group’s (CCTG) next randomized Phase II trial of double immunotherapy with durvalumab and tremelimumab versus quadruple therapy with durvalumab, tremelimumab, and platinum doublet chemotherapy (NCT03057106). Recorded at the 2016 World Conference of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.

Share this video